About the Company - ERIS Lifesciences Ltd
Eris Lifesciences Ltd. is a Public Limited Listed company incorporated on 25/01/2007 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24232GJ2007PLC049867 and registration number is 049867. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1215.73 Cr. and Equity Capital is Rs. 13.59 Cr. for the Year ended 31/03/2022.
Management |
---|
Name | Position Held |
---|
Mr. Amit Bakshi | Chairperson & Managing Director |
Mr. Krishnakumar Vaidyanathan | COO & Executive Director |
Mr. Inderjeet Singh Negi | Executive Director |
Mr. Kaushal Shah | Executive Director |
Mr. Rajeev Dalal | Independent Director |
Mr. Vasudevan Sujesh | Independent Director |
Ms. Kalpana Unadkat | Independent Director |
Mr. Prashant Gupta | Independent Director |
Eris Lifesciences Ltd. Share Price Update |
---|
Share Price | Value |
---|
Today | ₹943.10 |
Previous Day | ₹940.85 |
Basic Stock Data of ERIS Lifesciences Ltd
Market Cap | 12,830 Cr. |
---|
Current Price | 943 |
---|
High / Low | 972/551 |
---|
Stock P/E | 34.0 |
---|
Book Value | 177 |
---|
Dividend Yield | 0.78 % |
---|
ROCE | 16.7 % |
---|
ROE | 18.0 % |
---|
Face Value | 1.00 |
---|
ERIS Lifesciences Ltd Quarterly Results
Month | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|
Sales | 330 | 310 | 278 | 349 | 360 | 332 | 306 | 399 | 461 | 423 | 403 | 467 | 505 |
Expenses | 205 | 203 | 184 | 223 | 220 | 210 | 209 | 269 | 309 | 286 | 284 | 297 | 324 |
Operating Profit | 125 | 107 | 95 | 127 | 140 | 122 | 97 | 129 | 151 | 137 | 119 | 170 | 181 |
OPM % | 38% | 35% | 34% | 36% | 39% | 37% | 32% | 32% | 33% | 32% | 30% | 36% | 36% |
Other Income | 2 | 3 | 2 | 6 | 7 | 5 | 8 | 3 | 5 | 2 | 1 | 1 | 3 |
Interest | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 3 | 9 | 17 | 16 |
Depreciation | 11 | 11 | 11 | 15 | 15 | 17 | 18 | 23 | 29 | 30 | 35 | 41 | 42 |
Profit before tax | 116 | 99 | 85 | 117 | 131 | 109 | 85 | 101 | 121 | 107 | 76 | 112 | 126 |
Tax % | 7% | 9% | 19% | 9% | 9% | 8% | 6% | 8% | 1% | 6% | 19% | 17% | 3% |
Net Profit | 108 | 90 | 68 | 107 | 118 | 101 | 80 | 93 | 119 | 100 | 61 | 94 | 122 |
EPS in Rs | 7.93 | 6.64 | 5.03 | 7.86 | 8.71 | 7.41 | 5.91 | 6.96 | 8.85 | 7.49 | 4.81 | 6.98 | 9.07 |
ERIS Lifesciences Ltd Quarterly Chart
ERIS Lifesciences Ltd Profit & Loss
Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
---|
Sales | 274 | 393 | 509 | 546 | 597 | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 1,798 |
Expenses | 215 | 307 | 414 | 427 | 425 | 480 | 533 | 637 | 702 | 781 | 858 | 1,146 | 1,191 |
Operating Profit | 59 | 86 | 95 | 118 | 172 | 269 | 322 | 345 | 372 | 431 | 489 | 539 | 607 |
OPM % | 21% | 22% | 19% | 22% | 29% | 36% | 38% | 35% | 35% | 36% | 36% | 32% | 34% |
Other Income | 1 | 1 | 9 | 7 | 3 | 25 | 26 | 31 | 12 | 9 | 22 | 9 | 8 |
Interest | 1 | 1 | 0 | 0 | 0 | 1 | 11 | 23 | 2 | 2 | 4 | 26 | 46 |
Depreciation | 3 | 3 | 5 | 16 | 20 | 23 | 26 | 36 | 50 | 43 | 65 | 117 | 148 |
Profit before tax | 55 | 83 | 98 | 109 | 154 | 270 | 312 | 317 | 331 | 394 | 442 | 405 | 421 |
Tax % | 33% | 30% | 28% | 18% | 13% | 9% | 6% | 8% | 11% | 10% | 8% | 8% | |
Net Profit | 37 | 58 | 71 | 89 | 135 | 247 | 295 | 291 | 297 | 355 | 406 | 374 | 378 |
EPS in Rs | 2,686.55 | 4,232.73 | 5,121.45 | 6,489.45 | 9,714.18 | 17.95 | 21.39 | 21.15 | 21.84 | 26.16 | 29.88 | 28.10 | 28.35 |
Dividend Payout % | 0% | 0% | 0% | 0% | 63% | 0% | 0% | 0% | 13% | 21% | 20% | 26% | |
ERIS Lifesciences Ltd Profit & Loss Yearly Chart
ERIS Lifesciences Ltd Growth
|
Compounded Sales Growth |
---|
10 Years:: | 16% |
5 Years:: | 15% |
3 Years:: | 16% |
TTM:: | 20% |
ERIS Lifesciences Ltd Growth
|
Compounded Profit Growth |
---|
10 Years:: | 20% |
5 Years:: | 5% |
3 Years:: | 8% |
TTM:: | -4% |
ERIS Lifesciences Ltd Growth
|
Stock Price CAGR |
---|
10 Years:: | % |
5 Years:: | 9% |
3 Years:: | 21% |
1 Year:: | 38% |
ERIS Lifesciences Ltd Growth
|
Return on Equity |
---|
10 Years:: | 27% |
5 Years:: | 23% |
3 Years:: | 22% |
Last Year:: | 18% |
ERIS Lifesciences Ltd Balance Sheet
Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 |
---|
Equity Capital | 0 | 0 | 0 | 0 | 0 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Reserves | 48 | 106 | 176 | 266 | 299 | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,895 | 2,182 | 2,398 |
Borrowings | 5 | 3 | 1 | 1 | 0 | 1 | 377 | 176 | 0 | 7 | 84 | 877 | 830 |
Other Liabilities | 49 | 63 | 94 | 91 | 98 | 124 | 170 | 175 | 205 | 202 | 233 | 337 | 634 |
Total Liabilities | 102 | 172 | 271 | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 3,875 |
Fixed Assets | 23 | 27 | 75 | 72 | 71 | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 2,520 |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 2 | 27 | 22 | 58 |
Investments | 13 | 47 | 84 | 167 | 190 | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 22 |
Other Assets | 65 | 98 | 112 | 119 | 136 | 157 | 271 | 383 | 544 | 636 | 761 | 783 | 1,275 |
Total Assets | 102 | 172 | 271 | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 3,875 |
ERIS Lifesciences Ltd Reserves and Borrowings Chart
ERIS Lifesciences Ltd Cash Flow
Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|
Cash from Operating Activity | 30 | 38 | 90 | 90 | 131 | 200 | 235 | 223 | 271 | 375 | 378 | 292 |
Cash from Investing Activity | -19 | -36 | -83 | -92 | -44 | -184 | -590 | -5 | 123 | -323 | -320 | -975 |
Cash from Financing Activity | -10 | -3 | -2 | 0 | -84 | -24 | 363 | -221 | -335 | -82 | -45 | 688 |
Net Cash Flow | 1 | -1 | 5 | -2 | 4 | -8 | 8 | -3 | 60 | -30 | 14 | 5 |
|
ERIS Lifesciences Ltd Financial Efficiency Indicators
Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|
Debtor Days | 19 | 15 | 16 | 16 | 16 | 24 | 28 | 31 | 53 | 42 | 44 | 63 |
Inventory Days | 166 | 214 | 166 | 223 | 178 | 195 | 178 | 196 | 148 | 145 | 166 | 136 |
Days Payable | 133 | 109 | 138 | 142 | 92 | 134 | 247 | 200 | 213 | 157 | 166 | 129 |
Cash Conversion Cycle | 52 | 120 | 43 | 97 | 102 | 84 | -40 | 28 | -12 | 30 | 44 | 70 |
Working Capital Days | 18 | 31 | 7 | 15 | 9 | 23 | -13 | -17 | 59 | 64 | 76 | 92 |
ROCE % | | 98% | 64% | 47% | 53% | 60% | 34% | 26% | 25% | 27% | 25% | 17% |
ERIS Lifesciences Ltd Financial Efficiency Indicators Chart
No valid data available for the Shareholding
ERIS Lifesciences Ltd Shareholding Pattern Chart
No. of ERIS Lifesciences Ltd Shareholders
ERIS Lifesciences Ltd Mutual Fund Holdings
Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) |
---|
HDFC Small Cap Fund - Regular Plan | 5098713 | 1.89 | 438.23 |
UTI Flexi Cap Fund | 2573067 | 0.91 | 221.16 |
Franklin India Smaller Companies Fund | 1710900 | 1.52 | 147.05 |
Aditya Birla Sun Life Equity Hybrid 95 Fund | 1368030 | 1.7 | 117.58 |
UTI Value Fund | 1029126 | 1.19 | 88.45 |
HSBC Midcap Fund | 962580 | 1.03 | 82.73 |
HDFC Large and Mid Cap Fund - Regular Plan | 675000 | 0.49 | 58.02 |
UTI Mid Cap Fund | 591612 | 0.58 | 50.85 |
Tata ELSS Tax Saver Fund | 512000 | 1.27 | 44.01 |
UTI Dividend Yield Fund | 450000 | 1.26 | 38.68 |
ERIS Lifesciences Ltd ROCE Trend
ERIS Lifesciences Ltd EPS Trend
ERIS Lifesciences Ltd Key Financial Ratios
Month | Mar 23 | Mar 22 | Mar 21 | Mar 20 | Mar 19 |
---|
FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Basic EPS (Rs.) | 28.10 | 29.89 | 26.16 | 21.61 | 21.15 |
Diluted EPS (Rs.) | 28.07 | 29.88 | 26.14 | 21.59 | 21.13 |
Cash EPS (Rs.) | 36.12 | 34.61 | 29.32 | 25.54 | 23.81 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 163.30 | 140.35 | 116.10 | 95.47 | 84.99 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 163.30 | 140.35 | 116.10 | 95.47 | 84.99 |
Revenue From Operations / Share (Rs.) | 123.92 | 99.10 | 89.25 | 79.10 | 71.42 |
PBDIT / Share (Rs.) | 40.29 | 37.60 | 32.35 | 28.26 | 27.39 |
PBIT / Share (Rs.) | 31.68 | 32.84 | 29.19 | 24.56 | 24.74 |
PBT / Share (Rs.) | 29.76 | 32.53 | 29.05 | 24.40 | 23.08 |
Net Profit / Share (Rs.) | 27.51 | 29.85 | 26.16 | 21.84 | 21.17 |
NP After MI And SOA / Share (Rs.) | 28.10 | 29.88 | 26.16 | 21.84 | 21.15 |
PBDIT Margin (%) | 32.51 | 37.93 | 36.24 | 35.73 | 38.34 |
PBIT Margin (%) | 25.56 | 33.13 | 32.70 | 31.05 | 34.64 |
PBT Margin (%) | 24.01 | 32.82 | 32.55 | 30.85 | 32.31 |
Net Profit Margin (%) | 22.20 | 30.12 | 29.30 | 27.60 | 29.64 |
NP After MI And SOA Margin (%) | 22.67 | 30.14 | 29.30 | 27.60 | 29.60 |
Return on Networth / Equity (%) | 17.40 | 21.28 | 22.52 | 22.87 | 25.27 |
Return on Capital Employeed (%) | 13.36 | 21.53 | 23.76 | 24.03 | 27.26 |
Return On Assets (%) | 10.42 | 17.87 | 19.35 | 19.10 | 18.71 |
Long Term Debt / Equity (X) | 0.29 | 0.02 | 0.00 | 0.00 | 0.00 |
Total Debt / Equity (X) | 0.37 | 0.02 | 0.00 | 0.00 | 0.00 |
Asset Turnover Ratio (%) | 0.52 | 0.61 | 0.67 | 0.67 | 0.61 |
Current Ratio (X) | 1.73 | 3.14 | 2.80 | 2.91 | 1.90 |
Quick Ratio (X) | 1.43 | 2.55 | 2.23 | 2.49 | 1.63 |
Inventory Turnover Ratio (X) | 1.26 | 1.31 | 1.48 | 1.04 | 0.83 |
Dividend Payout Ratio (NP) (%) | 26.15 | 20.10 | 21.02 | 13.14 | 0.00 |
Dividend Payout Ratio (CP) (%) | 20.01 | 17.34 | 18.75 | 11.23 | 0.00 |
Earning Retention Ratio (%) | 73.85 | 79.90 | 78.98 | 86.86 | 0.00 |
Cash Earning Retention Ratio (%) | 79.99 | 82.66 | 81.25 | 88.77 | 0.00 |
Interest Coverage Ratio (%) | 20.94 | 123.26 | 243.78 | 177.51 | 16.45 |
Interest Coverage Ratio (Post Tax) (%) | 15.30 | 98.87 | 198.08 | 138.14 | 13.72 |
Enterprise Value (Cr.) | 8575.56 | 9359.51 | 8168.96 | 4936.17 | 8868.07 |
EV / Net Operating Revenue (X) | 5.09 | 6.95 | 6.74 | 4.60 | 9.03 |
EV / EBITDA (X) | 15.65 | 18.31 | 18.60 | 12.86 | 23.55 |
MarketCap / Net Operating Revenue (X) | 4.62 | 6.95 | 6.77 | 4.66 | 9.02 |
Retention Ratios (%) | 73.84 | 79.89 | 78.97 | 86.85 | 0.00 |
Price / BV (X) | 3.54 | 4.91 | 5.21 | 3.86 | 7.70 |
Price / Net Operating Revenue (X) | 4.62 | 6.95 | 6.77 | 4.66 | 9.02 |
EarningsYield | 0.04 | 0.04 | 0.04 | 0.05 | 0.03 |
ERIS Lifesciences Ltd Profitability Ratios (%)
ERIS Lifesciences Ltd Liquidity Ratios
ERIS Lifesciences Ltd Liquidity Ratios (%)
ERIS Lifesciences Ltd Interest Coverage Ratios (%)
ERIS Lifesciences Ltd Valuation Ratios
Fair Value of ERIS Lifesciences Ltd Stock
Fair Value: ₹1091.69
The stock is undervalued by 15.77% compared to the current price ₹943
*This is not Investment Advice
Strength and Weakness of ERIS Lifesciences Ltd Stock
Strength | Weakness |
---|
The company has shown consistent growth in sales and profit over the years. | The stock has a low average ROCE, which may not be favorable. The stock has a high average Working Capital Days, which may not be favorable. The stock has a high average Cash Conversion Cycle, which may not be favorable. The company has higher borrowings compared to reserves, which may suggest financial risk. |